Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | KMO | O15229 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26087840 | 0.88 | MAPT (0.64) | MAPTCYP1A2CYP2C9ALDH1A1CYP2C19 | |
| SCHEMBL15012807 | 0.86 | ALDH1A1 (0.52) | MAPTCYP1A2CYP2C9ALDH1A1CYP2C19 | |
| SCHEMBL25771498 | 0.82 | KMO (0.59) | MAPTCYP1A2CYP2C9ALDH1A1CYP2C19 | |
| SCHEMBL22652046 | 0.80 | ALDH1A1 (1.00) | MAPTCYP1A2CYP2C9ALDH1A1CYP2C19 | |
| SCHEMBL15543926 | 0.80 | MAPT (0.71) | MAPTCYP1A2CYP2C9ALDH1A1CYP2C19 | |
| SCHEMBL5338609 | 0.78 | KMO (0.55) | MAPTCYP1A2CYP2C9ALDH1A1CYP2C19 | |
| SCHEMBL780203 | 0.78 | MAPT (0.58) | MAPTCYP1A2CYP2C9ALDH1A1CYP2C19 | |
| SCHEMBL28153041 | 0.77 | KDM4E (0.61) | MAPTCYP1A2CYP2C9ALDH1A1CYP2C19 | |
| SCHEMBL22090007 | 0.77 | MAPT (0.67) | MAPTCYP1A2CYP2C9ALDH1A1CYP2C19 | |
| SCHEMBL20598470 | 0.76 | MAPT (0.66) | MAPTCYP1A2CYP2C9ALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8906910-B2 | Imidazopyridine derivatives as PI3 kinase | GLAXOSMITHKLINE LLC (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906910-B2 | Imidazopyridine derivatives as PI3 kinase | GLAXOSMITHKLINE LLC (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906910-B2 | Imidazopyridine derivatives as PI3 kinase | GLAXOSMITHKLINE LLC (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140323480-A1 | Imidazopyridine Derivatives As PI3 Kinase | Glaxo Smith Kline LLC a corporation | 2014-10-30 | — | — | US | disclosed |
| US-20140323480-A1 | Imidazopyridine Derivatives As PI3 Kinase | Glaxo Smith Kline LLC a corporation | 2014-10-30 | — | — | US | disclosed |
| US-20140323480-A1 | Imidazopyridine Derivatives As PI3 Kinase | Glaxo Smith Kline LLC a corporation | 2014-10-30 | — | — | US | disclosed |
| WO-2013095761-A1 | IMIDAZOPYRIDINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013095761-A1 | IMIDAZOPYRIDINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323480-A1 | Imidazopyridine Derivatives As PI3 Kinase | PIK3CD, PI4KA, PIK3CG | MAPT 4080/4885CYP1A2 2224/4885CYP2C9 1989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.